Loxo Oncol patents expiration
1. Jaypirca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 27, 2030 |
| New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor
Dosage: TABLET;ORAL
More Information on Dosage
JAYPIRCA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic